Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03168139 |
|
Recruitment Status :
Completed
First Posted : May 30, 2017
Last Update Posted : July 8, 2020
|
Sponsor:
TME Pharma AG
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
TME Pharma AG
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | March 25, 2020 |
| Actual Study Completion Date : | March 25, 2020 |